Have questions? Visit https://www.reddit.com/r/SNPedia

rs9282858

From SNPedia

Orientationminus
Stabilizedminus
Geno Mag Summary
(G;G) 0 common in clinvar
Make rs9282858(A;A)
Make rs9282858(A;G)
ReferenceGRCh38 38.1/142
Chromosome2
Position31580756
GeneSRD5A2
is asnp
is mentioned by
dbSNPrs9282858
ebirs9282858
HLIrs9282858
Exacrs9282858
Varsomers9282858
Maprs9282858
PheGenIrs9282858
hapmaprs9282858
1000 genomesrs9282858
hgdprs9282858
ensemblrs9282858
gopubmedrs9282858
geneviewrs9282858
scholarrs9282858
googlers9282858
pharmgkbrs9282858
gwascentralrs9282858
openSNPrs9282858
23andMers9282858
23andMe allrs9282858
SNP Nexus

SNPshotrs9282858
SNPdbers9282858
MSV3drs9282858
GWAS Ctlgrs9282858
GMAF0.01791
Max Magnitude0
"After evaluating over 6,000 cases and 6,000 controls, there is little evidence of a role for the SRD5A2 A49T (i.e. rs9282858) variant in prostate cancer risk."[PMID 18469342OA-icon.png]
OMIM607306
DescSTEROID 5-ALPHA-REDUCTASE POLYMORPHISM
Variant0012
Relatedalso
Neighborrs523349
Distance120


[PMID 19914946] Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review


ClinVar
Risk rs9282858(A;A)
Alt rs9282858(A;A)
Reference rs9282858(G;G)
Significance Non-pathogenic
Disease STEROID 5-ALPHA-REDUCTASE POLYMORPHISM not provided
Variation info
Gene SRD5A2
CLNDBN STEROID 5-ALPHA-REDUCTASE POLYMORPHISM not provided
Reversed 1
HGVS NC_000002.11:g.31805826C>T
CLNSRC OMIM Allelic Variant
CLNACC RCV000003511.4, RCV000083640.1,



[PMID 18163429OA-icon.png] Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.


[PMID 18566991OA-icon.png] Joint effects of inflammation and androgen metabolism on prostate cancer severity.


GET Evidence
SRD5A2-A48T
aa_change Ala48Thr
aa_change_short A48T
impact not reviewed
qualified_impact Insufficiently evaluated not reviewed
overall_frequency 0.0234955
summary



[PMID 26751392] Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.